CellaVision ABCVLLY +12.06%69 PS Ratio is 4.33 as of Jun. 24, 2026, which is 63% below its 10-year median of 11.55. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 804 Medical Devices & Instruments companies, CellaVision AB ranks worse than 66.29% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CellaVision AB's share price is $7.06.
CellaVision AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.63. Hence, CellaVision AB's PS Ratio for today is 4.33.
The historical rank and industry rank for CellaVision AB's PS Ratio or its related term are showing as below:
CVLLY'
s PS Ratio Range Over the Past 10 Years
Min: 3.87 Med: 11.55 Max: 22.67
Current: 4.47
During the past 13 years, CellaVision AB's highest PS Ratio was 22.67. The lowest was 3.87. And the median was 11.55.
CVLLY's PS Ratio is ranked worse than 66.29% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.855
vs CVLLY: 4.47
CellaVision AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of CellaVision AB was -2.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 13.00% per year.
During the past 13 years, CellaVision AB's highest 3-Year average Revenue per Share Growth Rate was 20.90% per year. The lowest was 5.90% per year. And the median was 13.30% per year.
Back to Basics: PS Ratio
CellaVision AB (OTCPK:CVLLY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
CellaVision AB PS Ratio Related Terms
CellaVision AB PS Ratio Historical Data
* Premium members only.
The historical data trend for CellaVision AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where CellaVision AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
CellaVision AB's Share Price of today is $7.06. CellaVision AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
CellaVision AB (CVLLY) has a PS Ratio of 4.33 as of Jun. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CellaVision AB and its competitors. This is 63% below median its historical median of 11.55. Over the past decade, CellaVision AB's PS Ratio has ranged from 3.87 to 22.67. According to the industry distribution chart, CellaVision AB ranks #533 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 66.3%.
Is CellaVision AB's PS Ratio too high?
CellaVision AB's current PS Ratio of 4.33 is 63% below median its 10-year median of 11.55. Over the past 10 years, this metric has ranged from a low of 3.87 to a high of 22.67. The Medical Devices & Instruments industry median PS Ratio is 2.86. CellaVision AB's value of 4.33 is 51.7% above this industry median. Based on the distribution chart, CellaVision AB ranks #533 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #533 out of 804 companies for PS Ratio. This places CellaVision AB in the lower half of its industry. The industry median PS Ratio is 2.86. CellaVision AB's value of 4.33 is 51.7% above this benchmark. Historically, CellaVision AB's own PS Ratio has ranged from 3.87 to 22.67 over the past decade. While the company's 10-year median is 11.55 vs. the industry median of 2.86, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.86, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current PS Ratio of 4.33 is 51.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current PS Ratio is 4.33, which is 63% below median its own 10-year median of 11.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current PS Ratio is 4.33, which is 63% below median its 10-year median of 11.55 and 51.7% above the Medical Devices & Instruments industry median of 2.86. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current PS Ratio is 4.33 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
PS Ratio: 4.33 (63% below median its 10-year median of 11.55)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 51.7% above the Medical Devices & Instruments median (#533 of 804)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
